Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20:596-604.Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM (2013) Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 20:596–604. : 10.2174/092986713804999303F. Lumachi, A. ...
Thus, research efforts have focused on finding alternative therapies to trastuzumab and lapatinib for the treatment of Her2-positive breast cancer. Efforts aimed at understanding the mechanism of action of trastuzumab and lapatinib and the causes of resistance have led to the identification of several ...
This article reviews the challenges and future options in the treatment of ErbB2- positive metastatic breast cancer. It summarizes a presentation from a symposium that was held at the ECCO 14 congress in 2007. Despite great progress in the management of ErbB2-positive metastatic breast cancer, si...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed th...
The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression--making metastatic disease far less common today--newer treatment advances ar... Gradishar,J William - 《Journal of the National Comprehensive ...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
Approximately 20% of TNBCs express PD-L1, and expression of PD-L1 is associated with poor prognosis in patients with breast cancer, particularly those with luminal B and basal-like subtypes, thus making aggressive phenotype ER-positive and TNBC attractive subtypes in which to investigate PD-L1 ...
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody鈥揅ytotoxic Drug Conjugate Purpose Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermalgrowth factor receptor ... GDL Phillips,G Li,DL Dugger,... 被引量...
This chapter is a general overview briefly describing the treatment of breast cancer, intended to aid understanding of the various cases that will be mentioned in this book. Treatment for breast cancer includes local and systemic treatments, which are divided into pre-surgery neoadjuvant therapy and...
Objective To investigate the clinical effectiveness of treatment combining trastuzumab and taxanes in patients with human epidermal growth factor receptor ... - 《Womens Health》 被引量: 5发表: 2010年 Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases Objec...